ArticleNeurology open access2025

Tolebrutinib Phase 2b Long-Term Extension Study: Two-Year Safety, MRI, and Clinical Efficacy Outcomes in Patients With Relapsing Multiple Sclerosis Patients.

Jiwon Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.